The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.
Andrew David Norden
No relevant relationships to disclose
David Schiff
No relevant relationships to disclose
Manmeet Singh Ahluwalia
No relevant relationships to disclose
Glenn Jay Lesser
No relevant relationships to disclose
Lakshmi Nayak
No relevant relationships to disclose
Eudocia Quant Lee
No relevant relationships to disclose
Mikael L. Rinne
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Jorg Dietrich
No relevant relationships to disclose
Benjamin Purow
No relevant relationships to disclose
Katrina H. Smith
No relevant relationships to disclose
Sarah C. Gaffey
No relevant relationships to disclose
Christine Sceppa McCluskey
No relevant relationships to disclose
Keith L. Ligon
No relevant relationships to disclose
David A. Reardon
No relevant relationships to disclose
Patrick Y. Wen
Research Funding - Boehringer Ingelheim